Neurology

MS is difficult to diagnose because progression of the disease occurs at different rates.

Multiple sclerosis is a chronic autoimmune, inflammatory neurologic disease of the central nervous system that affects more than 400,000 individuals in the United States and 2.5 million individuals worldwide.

Nanoparticles found to stop disease progression in a model of chronic MS.

Natalizumab linked to increased risk biomarkers for virus that can lead to potentially fatal condition.

Targeting enzyme found to slow progression of MS in human cells.

Findings may lead to new treatment that protects nerves from damage caused in optic neuritis and throughout the central nervous system during MS attacks.

Serum antibody repertoires may serve as biomarkers for the pathology and progression of multiple sclerosis.

Few MS patients are treated for depression through psychotherapy or pharmaceutical therapy.

Iron accumulation may precede more pronounced brain atrophy.

Evidence shows demyelination and neuroaxonal abnormalities occur in both the white and grey matter of MS patients.

A joint scientific statement appears to be formulating the building blocks to amend the guidelines for alteplase.

Estrogen found to reduce the ability of the immune system to attack the brain in MS patients.

Acceptance is a multiple sclerosis treatment goal because it is associated with better drug adherence.

Study finds presence of additional environmental risk factors affect the etiology of multiple sclerosis.

Fingolimid is an oral treatment for relapsing-remitting multiple sclerosis.

Fingolimid is an oral treatment for relapsing-remitting multiple sclerosis.

Process attaches disease-related protein fragments to spleen cells to prevent MS.

B cells can contribute to abnormal immune responses in MS patients.

Vitamin D3 found to aid immune response regulation among patients with MS.

Interventions needed to get MS patients more active.

Most read multiple sclerosis articles from the past year.

Long chain fatty acids found to promote the development and propagation of inflammatory cells.

Average MS onset for patients who spent time in the sun every day is nearly two years later than patients who did not spend daily time in the sun.

MS patients with visual problems perform worse in testing than patients without visual problems but with MS.

MS drug previously refused market authorization because of cancer concerns.